CV Sciences (CVSI) 10-Q 15 Aug 22 2022 Q2 Quarterly report Financial data

COVER

COVER - shares	6 Months Ended
	Jun. 30, 2022	Aug. 12, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	000-54677
Entity Registrant Name	CV Sciences, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	80-0944970
Entity Address, Address Line One	9530 Padgett Street, Suite 107
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92126
City Area Code	866
Local Phone Number	290-2157
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		147,793,880
Entity Central Index Key	0001510964
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022

CONDENSED BALANCE SHEETS (UNAUD

CONDENSED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 1,114	$ 1,375
Accounts receivable, net	951	2,041
Inventory	7,357	8,624
Prepaid expenses and other	3,217	2,146
Total current assets	12,639	14,186
Property & equipment, net	698	1,717
Right of use assets	326	0
Intangibles	1,485	1,485
Other assets	610	678
Total assets	15,758	18,066
Current liabilities:
Accounts payable	2,473	2,624
Accrued expenses	9,931	10,915
Operating lease liability - current	111	0
Convertible notes	952	612
Debt	89	310
Total current liabilities	13,556	14,461
Operating lease liability	249	0
Deferred tax liability	62	62
Total liabilities	13,867	14,523
Commitments and contingencies
Stockholders' equity
Preferred stock, par value $0.0001; 10,000 shares authorized; no shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	0	0
Common stock, par value $0.0001; 790,000 and 190,000 shares authorized as of June 30, 2022 and December 31, 2021, respectively; 139,955 and 112,482 shares issued and outstanding as of June 30, 2022 and December 31, 2021, respectively	14	11
Additional paid-in capital	86,222	83,007
Accumulated deficit	(84,345)	(79,475)
Total stockholders' equity	1,891	3,543
Total liabilities and stockholders' equity	$ 15,758	$ 18,066

CONDENSED BALANCE SHEETS (UNA_2

CONDENSED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares	Jun. 30, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock par value (in USD per share)	$ 0.0001	$ 0.0001
Preferred stock authorized (in shares)	10,000,000	10,000,000
Preferred stock issued (in shares)	0	0
Preferred stock outstanding (in shares)	0	0
Common stock par value (in USD per share)	$ 0.0001	$ 0.0001
Common stock authorized (in shares)	790,000,000	190,000,000
Common stock issued (in shares)	139,955,000	112,482,000
Common stock outstanding (in shares)	139,955,000	112,482,000

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Product sales, net	$ 4,138	$ 5,128	$ 8,585	$ 9,972
Cost of goods sold	2,868	2,838	6,159	5,324
Gross profit	1,270	2,290	2,426	4,648
Operating expenses:
Research and development	102	225	223	411
Selling, general and administrative	3,483	5,575	6,033	10,860
Total operating expenses	3,585	5,800	6,256	11,271
Operating loss	(2,315)	(3,510)	(3,830)	(6,623)
Interest expense	336	9	1,038	23
Loss before income taxes	(2,651)	(3,519)	(4,868)	(6,646)
Income tax expense	2	11	2	11
Net loss	(2,653)	(3,530)	(4,870)	(6,657)
Deemed dividend for beneficial conversion of Series A convertible preferred stock	920	0	920	0
Net loss attributable to common stockholders	(3,573)	(3,530)	(5,790)	(6,657)
Net loss attributable to common stockholders	$ (3,573)	$ (3,530)	$ (5,790)	$ (6,657)
Weighted average common shares outstanding, basic (in shares)	135,414	107,623	127,104	106,074
Weighted average common shares outstanding, diluted (in shares)	135,414	107,623	127,104	106,074
Net loss per share attributable to common stockholders, basic (in USD per share)	$ (0.03)	$ (0.03)	$ (0.05)	$ (0.06)
Net loss per share attributable to common stockholders, diluted (in USD per share)	$ (0.03)	$ (0.03)	$ (0.05)	$ (0.06)
Revenue, product and service [Extensible List]	Product [Member]	Product [Member]	Product [Member]	Product [Member]

CONDENSED STATEMENTS OF STOCKHO

CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED) - USD ($) shares in Thousands, $ in Thousands	Total	Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2020		0	100,664
Beginning balance at Dec. 31, 2020	$ 11,212	$ 0	$ 10	$ 75,123	$ (63,921)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under equity commitment (shares)			6,127
Issuance of common stock under equity commitment	3,222		$ 1	3,221
Stock-based compensation	657			657
Net loss	(3,127)				(3,127)
Ending balance (in shares) at Mar. 31, 2021		0	106,791
Ending balance at Mar. 31, 2021	11,964	$ 0	$ 11	79,001	(67,048)
Beginning balance (in shares) at Dec. 31, 2020		0	100,664
Beginning balance at Dec. 31, 2020	11,212	$ 0	$ 10	75,123	(63,921)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(6,657)
Ending balance (in shares) at Jun. 30, 2021		0	108,462
Ending balance at Jun. 30, 2021	9,977	$ 0	$ 11	80,544	(70,578)
Beginning balance (in shares) at Mar. 31, 2021		0	106,791
Beginning balance at Mar. 31, 2021	11,964	$ 0	$ 11	79,001	(67,048)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock under equity commitment (shares)			1,669
Issuance of common stock under equity commitment	631			631
Issuance of common stock from net exercise of stock options (in shares)			2
Issuance of common stock from net exercise of stock options	0
Stock-based compensation	912			912
Net loss	(3,530)				(3,530)
Ending balance (in shares) at Jun. 30, 2021		0	108,462
Ending balance at Jun. 30, 2021	9,977	$ 0	$ 11	80,544	(70,578)
Beginning balance (in shares) at Dec. 31, 2021		0	112,482
Beginning balance at Dec. 31, 2021	3,543	$ 0	$ 11	83,007	(79,475)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of preferred stock and common stock warrants, net of issuance costs (shares)		1
Issuance of preferred stock and common stock warrants, net of issuance costs	554	$ 280		274
Issuance of common stock from note conversion (in shares)			6,804
Issuance of common stock from note conversion	1,229		$ 1	1,228
Common stock issued for services (in shares)			3,496
Common stock issued for services	384			384
Stock-based compensation	516			516
Net loss	(2,217)				(2,217)
Ending balance (in shares) at Mar. 31, 2022		1	122,782
Ending balance at Mar. 31, 2022	4,009	$ 280	$ 12	85,409	(81,692)
Beginning balance (in shares) at Dec. 31, 2021		0	112,482
Beginning balance at Dec. 31, 2021	3,543	$ 0	$ 11	83,007	(79,475)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss	(4,870)
Ending balance (in shares) at Jun. 30, 2022		0	139,955
Ending balance at Jun. 30, 2022	1,891	$ 0	$ 14	86,222	(84,345)
Beginning balance (in shares) at Mar. 31, 2022		1	122,782
Beginning balance at Mar. 31, 2022	4,009	$ 280	$ 12	85,409	(81,692)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock from note conversion (in shares)			7,173
Issuance of common stock from note conversion	389		$ 1	388
Conversion of preferred stock (in shares)		(1)	10,000
Conversion of preferred stock	0	$ (280)	$ 1	279
Beneficial conversion charge for preferred stock conversion	0	(920)		920
Deemed dividend	0	$ 920		(920)
Common stock issued for services (in shares)			3,496
Common stock issued for services			$ 400
Stock-based compensation	146			146
Net loss	(2,653)				(2,653)
Ending balance (in shares) at Jun. 30, 2022		0	139,955
Ending balance at Jun. 30, 2022	$ 1,891	$ 0	$ 14	$ 86,222	$ (84,345)

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
OPERATING ACTIVITIES
Net loss	$ (4,870)	$ (6,657)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation and amortization	860	402
Stock-based compensation	662	1,569
Loss on disposal of fixed assets	159	0
Convertible note discount and interest expense	1,034	0
Employee retention credit benefit	(1,993)	0
Non-cash lease expense, net	19	268
Other	205	211
Change in operating assets and liabilities:
Accounts receivable, net	1,019	(85)
Inventory	1,267	(336)
Prepaid expenses and other	885	822
Accounts payable and accrued expenses	(795)	(947)
Net cash used in operating activities	(1,548)	(4,753)
INVESTING ACTIVITIES
Purchases of property and equipment	0	(35)
Net cash flows used in investing activities	0	(35)
FINANCING ACTIVITIES
Proceeds from issuance of preferred stock and common stock warrants, net of issuance costs	554	0
Proceeds from issuance of convertible notes, net of issuance costs	954	0
Proceeds from issuance of common stock	0	3,853
Repayment of unsecured debt	(221)	(629)
Net cash flows provided by financing activities	1,287	3,224
Net decrease in cash, cash equivalents and restricted cash	(261)	(1,564)
Cash, cash equivalents and restricted cash, beginning of period	1,375	4,525
Cash, cash equivalents and restricted cash, end of period	1,114	2,961
Supplemental cash flow disclosure:
Interest paid	4	7
Supplemental disclosures of non-cash transactions:
Convertible note principal conversion into shares of common stock	(1,030)	0
Services paid with common stock	384	0
Right of use ("ROU") assets obtained in exchange for lease liability	$ 345	$ 0

ORGANIZATION AND BUSINESS

ORGANIZATION AND BUSINESS	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BUSINESS	ORGANIZATION AND BUSINESS Historical Information - CV Sciences, Inc. (the “Company”) was incorporated under the name Foreclosure Solutions, Inc. in the State of Texas on December 9, 2010. The Company subsequently changed its name to CannaVest Corp. (Texas) on January 29, 2013. On July 26, 2013, the Company merged with and into its wholly-owned Delaware subsidiary, CannaVest Corp (Delaware), to effectuate a change in the Company’s state of incorporation from Texas to Delaware. On January 4, 2016, the Company filed a Certificate of Amendment of Certificate of Incorporation reflecting its corporate name change to “CV Sciences, Inc.”, effective on January 5, 2016. In addition, on January 4, 2016, the Company amended its Bylaws to reflect its corporate name change to “CV Sciences, Inc.” Description of Business - The Company has two operating segments: consumer products and specialty pharmaceutical. The consumer products segment develops, manufactures, markets and sells hemp extracts and other proven science-backed, natural ingredients and products. The Company sells its products under tradenames, such as PlusCBD ™, HappyLane ™, ProCBD ™, CV ™ Acute , and CV ™ Defense . The Company's products are sold in a variety of market sectors including nutraceutical, beauty care and specialty foods. The specialty pharmaceutical segment is developing drug candidates which use cannabidiol ("CBD") as a primary active ingredient. Basis of Presentation - The unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") for interim financial information and the instructions to Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, the interim financial information includes all normal recurring adjustments necessary for a fair statement of the results for the interim periods. These condensed financial statements are unaudited and should be read in conjunction with the Company's Annual Report on Form 10-K for its fiscal year ended December 31, 2021. Operating results for interim periods are not necessarily indicative of operating results for an entire fiscal year. Liquidity Considerations – U.S. GAAP requires management to assess a company's ability to continue as a going concern within one year from the financial statement issuance and to provide related note disclosure in certain circumstances. The accompanying financial statements and notes have been prepared assuming the Company will continue as a going concern. For the six months ended June 30, 2022 and the year ended December 31, 2021, the Company generated negative cash flows from operations of $1.5 million and $7.5 million, respectively. In addition, the Company had an accumulated deficit of $84.3 million as of June 30, 2022. Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operations, growth initiatives and to continue to make and implement strategic cost reductions, including reductions in employee headcount, vendor spending, and delaying expenses related to its drug development activities. The Company intends to position itself so that it will be able to raise additional funds through the capital markets, issuance of debt, and/or securing lines of credit. In March 2022, the Company closed a second tranche of its convertible note offering and a convertible preferred stock financing, which resulted in gross proceeds to the Company before closing expenses of approximately $1.0 million and $0.7 million, respectively. Under the provisions of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) signed into law on March 27, 2020 and the subsequent extension of the CARES Act, the Company was eligible for a refundable employee retention credit subject to certain criteria. The Company determined that it qualifies for the tax credit under the CARES Act. In March 2022, the Company claimed employee retention credits, which are recognized as a reduction to general and administrative expenses of $2.0 million during the six months ended June 30, 2022. The amount is included in prepaid expenses and other in the Company's condensed balance sheet as of June 30, 2022. The Company's operating results and accumulated deficit, amongst other factors, raise substantial doubt about the Company's ability to continue as a going concern. The Company will continue to pursue the actions outlined above, as well as work towards increasing revenue and operating cash flows to meet its future liquidity requirements. However, there can be no assurance that the Company will be successful in any capital-raising efforts that it may undertake, and the failure of the Company to raise additional capital could adversely affect its future operations and viability. Use of Estimates - The preparation of the condensed financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the condensed financial statements and accompanying notes. Actual results may differ from these estimates. Significant estimates include the valuation of intangible assets, inputs for valuing equity awards, valuation of inventory and assumptions related to revenue recognition. Fair Value Measurements - Fair value is defined as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The carrying values of accounts receivable, other current assets, accounts payable, and certain accrued expenses as of June 30, 2022 and December 31, 2021, approximate their fair value due to the short-term nature of these items. The Company's debt balance also approximates fair value as of June 30, 2022 and December 31, 2021, as the interest rate on the debt approximates the rates available to the Company as of such dates. The estimated fair value for the convertible notes payable is not readily determinable because of the numerous provisions in the notes, including conversion terms. The accounting guidance establishes a three-level hierarchy for disclosure that is based on the extent and level of judgment used to estimate the fair value of assets and liabilities. • Level 1 - uses unadjusted quoted prices that are available in active markets for identical assets or liabilities. The Company does not have any assets or liabilities that are valued using inputs identified under a Level 1 hierarchy as of June 30, 2022 and December 31, 2021. • Level 2 - uses inputs other than quoted prices included in Level 1 that are either directly or indirectly observable through correlation with market data. These include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; and inputs to valuation models or other pricing methodologies that do not require significant judgment because the inputs used in the model, such as interest rates and volatility, can be corroborated by readily observable market data. The Company did not have any assets or liabilities that are valued using inputs identified under a Level 2 hierarchy as of June 30, 2022 and December 31, 2021. • Level 3 - uses one or more significant inputs that are unobservable and supported by little or no market activity, and that reflect the use of significant management judgment. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques, and significant management judgment or estimation. The Company did not have any assets or liabilities that are valued using inputs identified under a Level 3 hierarchy as of June 30, 2022 and December 31, 2021. Cash, cash equivalents, and restricted cash - The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheets to the total of the same amounts shown in the statement of cash flows for the six months ended June 30, 2022 and 2021 (in thousands): June 30, June 30, Cash and cash equivalents $ 1,114 $ 2,460 Restricted cash — 501 Total cash, cash equivalents and restricted cash shown in the statements of cash flows $ 1,114 $ 2,961 Revenues - The following presents product sales by retail (B2B) and e-commerce (B2C) channels for the three and six months ended June 30, 2022 and 2021: Three months ended June 30, 2022 Three months ended June 30, 2021 Amount % of product sales, net Amount % of product sales, net (in thousands) (in thousands) Retail sales (B2B) $ 2,292 55.4 % $ 3,235 63.1 % E-Commerce sales (B2C) 1,846 44.6 % 1,893 36.9 % Product sales, net $ 4,138 100.0 % $ 5,128 100.0 % Six months ended June 30, 2022 Six months ended June 30, 2021 Amount % of product sales, net Amount % of product sales, net (in thousands) (in thousands) Retail sales (B2B) $ 4,851 56.5 % $ 6,210 62.3 % E-Commerce sales (B2C) 3,734 43.5 % 3,762 37.7 % Product sales, net $ 8,585 100.0 % $ 9,972 100.0 % Common Stock Warrants - The Company classifies as equity any warrants that (i) require physical settlement or net-share settlement or (ii) provide the Company with a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company assesses classification of its common stock warrants and other freestanding derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required. The Company’s freestanding derivatives consist of warrants to purchase common stock that were issued in connection with its convertible preferred stock. The Company evaluated these warrants to assess their proper classification, and determined that the common stock warrants meet the criteria for equity classification in the balance sheets. Intangible Assets – The Company evaluates the carrying value of intangible assets annually during the fourth quarter in accordance with ASC Topic 350, Intangibles Goodwill and Other, and between annual evaluations if events occur or circumstances change that would more likely than not reduce the fair value of the asset below its carrying amount. Such circumstances could include, but are not limited to (1) a significant adverse change in legal factors or in business climate, (2) unanticipated competition, or (3) an adverse action or assessment by a regulator. All of the Company's intangible assets are assigned to the Company's specialty pharmaceutical segment. Management makes critical assumptions and estimates in completing impairment assessments of other intangible assets. The Company's cash flow projections look several years into the future and include assumptions on variables such as product development, future sales and operating margin growth rates, economic conditions, probability of success, market competition, inflation and discount rates. The Company classifies intangible assets into two categories: (1) intangible assets with definite lives subject to amortization; and (2) intangible assets with indefinite lives not subject to amortization. The Company determines the useful lives of its identifiable intangible assets after considering the specific facts and circumstances related to each intangible asset. Factors considered when determining useful lives include the contractual term of any agreement related to the asset, the historical performance of the asset, the Company's long-term strategy for using the asset, any laws or regulations which could impact the useful life of the asset and other economic factors, including competition and specific market conditions. Intangible assets that are deemed to have definite lives are amortized, primarily on a straight-line basis, over their useful lives to their estimated residual values, generally five years. In-process research & development ("IPR&D") has an indefinite life and is not amortized until completion and development of the project, at which time the IPR&D becomes an amortizable asset. Until such time as the projects are either completed or abandoned, the Company tests those assets for impairment at least annually at year end, or more frequently at interim periods, by evaluating qualitative factors which could be indicative of impairment. Qualitative factors being considered include, but are not limited to, macro-economic conditions, progress on drug development activities, and overall financial performance. If impairment indicators are present as a result of the Company's qualitative assessment, the Company will test those assets for impairment by comparing the fair value of the assets to their carrying value. Quantitative factors being considered include, but are not limited to, the current project status, forecasted changes in the timing or amounts required to complete the project, forecasted changes in timing or changes in the future cash flows to be generated by the completed products, a probability of success of the ultimate project and changes to other market-based assumptions, such as current Company market capitalization and estimates of the fair value of the Company's reporting units. Upon completion or abandonment, the value of the IPR&D assets will be amortized to expense over the anticipated useful life of the developed products, if completed, or charged to expense when abandoned if no alternative future use exists. Recent Accounting Pronouncements Not Yet Adopted In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments and subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04 and ASU 2019-05 (collectively, “Topic 326”). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. Topic 326 was to be effective for reporting periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates, which deferred the effective dates for the Company, as a smaller reporting company, until fiscal year 2023. The Company currently plans to adopt the aforementioned guidance at the beginning of fiscal 2023. The Company is currently evaluating the potential impact of Topic 326 on the Company’s condensed financial statements. Recent Adopted Pronouncements In August 2020, the FASB issued ASU No. 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity,” or ASU 2020-06. ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by reducing the number of accounting models and limiting the number of embedded conversion features separately recognized from the primary contract. The guidance also includes targeted improvements to the disclosures for convertible instruments and earnings per share. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years and early adoption is permitted in annual reporting periods ending after December 15, 2020. The Company adopted this guidance as of January 1, 2021, using the full retrospective method of adoption. Adoption of this guidance eliminated the presentation of the beneficial conversion feature on the statement of operations, delayed recognition of beneficial conversion amounts until they are triggered, and had no other material impact on the Company.

BALANCE SHEET DETAILS

BALANCE SHEET DETAILS	6 Months Ended
	Jun. 30, 2022
Condensed Financial Information Disclosure [Abstract]
BALANCE SHEET DETAILS	BALANCE SHEET DETAILS Inventory Inventory as of June 30, 2022 and December 31, 2021 was comprised of the following (in thousands): June 30, December 31, Raw materials $ 3,635 $ 4,023 Work in process 1,605 1,286 Finished goods 2,117 3,315 $ 7,357 $ 8,624 The Company recorded inventory write-downs of $0.1 million and $0.2 million for the three and six months ended June 30, 2022, respectively. Inventory write-offs for the three and six months ended June 30, 2021 were $0.1 million. Intangibles, net Intangible assets consisted of in-process research and development with an indefinite life of $1.5 million as of June 30, 2022 and December 31, 2021. Accrued expenses Accrued expenses as of June 30, 2022 and December 31, 2021 were as follows (in thousands): June 30, December 31, Accrued payroll expenses (1) $ 8,450 $ 9,023 Other accrued liabilities 1,481 1,892 $ 9,931 $ 10,915 (1) This includes a $6.7 million tax liability associated with a related party transaction, as discussed in Note 12.

LEASES

LEASES	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
LEASES	LEASES In April 2022, the Company entered into a new lease agreement for its main office facility. The facility is approximately 6,000 square feet and located in San Diego, California. The lease term is three years with a total lease obligation of approximately $0.4 million. The lease does not include an option to renew. The operating lease is included in "Right of use assets" on the Company's June 30, 2022 Condensed Balance Sheet, and represents the Company's right to use the underlying asset for the lease term. The Company's obligation to make lease payments is included in "Operating lease liability - current" and "Operating lease liability" on the Company's June 30, 2022 Condensed Balance Sheet. Based on the present value of the lease payments for the remaining lease term, the Company recognized an operating lease asset of $0.3 million and lease liabilities for operating leases of $0.4 million, respectively, on May 1, 2022. As of June 30, 2022, the Company had an operating lease obligation of $0.4 million and operating lease asset of $0.3 million related to the new facility. Operating lease expense is recognized on a straight-line basis over the lease term. During the three and six months ended June 30, 2022, the Company's total lease cost was immaterial. Because the rate implicit in the lease is not readily determinable, the Company uses the rate of interest that a lessee would have to pay to borrow on a collateralized basis over a similar term in an amount equal to the lease payments in a similar economic environment. Information related to the Company's operating lease assets and related lease liabilities were as follows: June 30, 2022 Remaining lease term (in months) 35 Discount rate 7.0 % Maturities of lease liabilities as of June 30, 2022 were as follows (in thousands): Year ending December 31, 2022 (remaining six months) $ 66 2023 135 2024 139 2025 60 400 Less imputed interest (40) Total lease liabilities $ 360 Current operating lease liabilities $ 111 Non-current operating lease liabilities 249 Total lease liabilities $ 360

CONVERTIBLE NOTES

CONVERTIBLE NOTES	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
CONVERTIBLE NOTES	CONVERTIBLE NOTES Convertible notes as of June 30, 2022 and December 31, 2021 were as follows (in thousands): June 30, 2022 December 31, 2021 Principal amount $ 2,120 $ 1,060 Less: Original issuance discount ("OID") (120) (60) Less: Debt issuance costs (275) (229) Net proceeds 1,725 771 Default premium 178 — Conversion of note into common shares (1,260) (230) Accretion of OID and amortization of debt issuance costs 309 71 Carrying amount $ 952 $ 612 On November 14, 2021, the Company entered into a securities purchase agreement (the “SPA”) with an institutional investor (the “Investor”) providing for the sale and issuance in series of registered direct offerings of senior convertible notes (“Notes”) in the aggregate original principal amount of up to $5.3 million (the “Offering”). On November 17, 2021, at the initial closing of this Offering, the Company sold and issued $1.06 million in aggregate principal amount of Notes to the Investor pursuant to a prospectus supplement to its effective shelf registration statement Form S-3 (Registration No. 333-237772) (the "Registration Statement"). The Notes have an OID of 6%, resulting in net proceeds to the Company of $1.0 million before other debt issuance costs, and mature on May 17, 2022. The Notes shall not bear interest except upon the occurrence of an event of default. After the occurrence of an event of default, the Notes will accrue interest at the rate of 15% per annum; provided, however, that in the event that such event of default is subsequently cured (and no other default then exists (including, without limitation, for the Company's failure to timely pay such interest at the default rate)), interest shall cease to accrue as of the calendar day immediately following the date of such cure. The Notes are senior to other indebtedness of the Company. The Notes have an initial fixed conversion price of $0.2611. The initial fixed conversion price is subject to proportional adjustment upon the occurrence of any stock split, stock dividend, stock combination and/or similar transactions and full-ratchet adjustment in connection with a subsequent offering at a per share price less than the fixed conversion price then in effect. Upon each additional closing, the fixed conversion price of all outstanding Notes is subject to downward adjustment if greater than the lower of (i) 120% of the closing bid price of the Company's common stock on the trading day immediately preceding such additional closing date; and (ii) 120% of the arithmetic average of the volume weighted average prices of the Company's common stock on the five trading days preceding the additional closing. The holder may convert any part of the Notes into shares of common stock at an “Alternate Conversion Price” equal to the lesser of (i) the fixed conversion price then in effect; (ii) the greater of the floor price of $0.01 and 90% of the arithmetic average of the three lowest daily volume weighted average prices of the Company's common stock during the ten trading days immediately prior to such conversion; and (iii) the greater of the floor price and 97% of the lowest sale price of the Company's common stock on the applicable conversion date. In connection with a change of control of the Company, each holder may require the Company to redeem in cash any portion of the Notes at the greater of the face value, a 15% redemption premium to the equity value of our common stock underlying the Notes and the equity value of the change of control consideration payable to the holder of common stock underlying the Notes. The equity value of our common stock underlying the Notes is calculated using the greatest closing sale price of Company common stock during the period immediately preceding the consummation or the public announcement of the change of control and ending the date the holder gives notice of such redemption. The equity value of the change of control consideration payable to the holder of common stock underlying the Notes is calculated using the aggregate cash consideration per share of common stock to be paid to the holders of common stock upon the change of control. If an event of default occurs, each holder may require the Company to redeem all or any portion of the Notes (including all accrued and unpaid interest and late charges thereon), in cash, at the greater of the face value and a 15% redemption premium or (10% if such event of default is a price default) to the greater of the face value and the equity value of the common stock underlying the Notes. The equity value of the common stock underlying the Notes is calculated using the greatest closing sale price of the common stock on any trading day immediately preceding such event of default and the date the entire payment is made. If the Company consummates a subsequent public or private offering of securities, each holder of Notes may require the Company to use up to 20% of the gross proceeds of such subsequent placement (less any reasonable placement agent, underwriter and/or legal fees and expenses) to redeem in cash all, or any portion, of the Notes, at a 5% redemption premium. The Company may redeem, at any time, any portion of the outstanding Notes in cash with a 15% redemption premium to the greater of the face value of the Notes or the equity value of its common stock. On March 25, 2022, the Company sold and issued an additional $1.06 million in principal amount of the Notes under this Offering (the "Second Tranche"), which Notes were offered pursuant to a prospectus supplement to the Registration Statement. The Notes issued in the Second Tranche also have an OID of 6%, resulting in net proceeds of the Company of $1.0 million, before other debt issuance costs. The Notes issued in the Second Tranche have the same material terms as those issued in the first tranche, but mature on September 25, 2022. The Notes issued in the second tranche have an initial conversion price of $0.1508, and pursuant to the Notes, upon closing of second tranche, the initial conversion price of the Notes issued in the first tranche in November 2021 was adjusted down from $0.2611 to $0.1508 as well. The Company did not repay the Notes issued in November in full on May 17, 2022, the maturity date, resulting in an event of default under such Notes. As a result of such default, the Notes issued in November, in the principal amount of $130,000 as of such date, began accruing interest at a rate of 15% per annum. Additionally, the default triggered the investor’s right under the Notes to require the Company to redeem all or any portion of the November Notes, in cash, at a price not less than the face value of such Notes plus a 15% redemption premium (the “Redemption Premium”). On May 18, 2022, the Company entered into a Forbearance Agreement with the investor, pursuant to which the investor agreed to forebear exercising any rights or remedies that it may have under the November Notes that arise as a result of the default until the earlier of (i) the date immediately prior to the date of occurrence of a Bankruptcy Event of Default (as defined in the Notes), (ii) the date of occurrence of any other event of default under Section 4(a) of the Notes, (iii) the time of any breach by the Company pursuant to the Forbearance Agreement, and (v) June 1, 2022 (such period, the “Forbearance Period”). In accordance with the Forbearance Agreement, the Company agreed to pay the investor the aggregate outstanding principal on the November Note at the Redemption Premium, including all accrued and unpaid interest, upon expiration of the Forbearance Period. As of May 31, 2022, prior to expiration of the Forbearance Period, the investor had converted the outstanding balance (including the redemption premium and accrued interest) due under the Notes issued in November, amounting to $151,772, into an aggregate of 3,751,971 shares of Company common stock at a conversion price of $0.04 per share. As a result, the Notes issued in November terminated. During the three and six months ended June 30, 2022, the volume weighted average price ("VWAP") of the Company's common stock was below $0.10 for more than 5 days, which constitutes a price default in accordance with the Notes. As a result, from the date of such default and for so long as such default remains uncured, the Notes that remain outstanding will accrue interest at a rate of 15% per annum. Following such default, the holder also added a 15% per annum default premium to the outstanding balance in accordance with the Notes. In addition, the holder now has the right to require the Company to redeem all or any portion of the Notes (including all accrued and unpaid interest and late charges thereon), in cash, at a price not less than the face value of the Notes and a 10% redemption premium, as determined in accordance with the terms of the Notes. The Company is in communications with the holder of the Notes regarding the default, and anticipates to come to a mutually agreeable resolution related thereto, although no assurances can be given. The Company recorded accrued interest of $29,000 as of June 30, 2022. There was no accrued interest as of December 31, 2021. During the three and six months ended June 30, 2022, holders of certain Notes converted amounts payable under such Notes into an aggregate of 7,172,244 and 13,976,525 shares of Company common stock at a weighted average conversion price of $0.05 and $0.07 per share, resulting in a reduction of the Note balance of $0.4 million and $1.0 million, respectively. In addition, the Company recognized additional interest expense associated with the conversion $0.6 million during the six months ended June 30, 2022. Additional interest expense for the three months ended June 30, 2022 were immaterial. Subsequent to June 30, 2022, holders of certain of the Notes converted amounts payable under such Notes into an additional 7,308,876 shares of Company common stock at a weighted average conversion price of $0.03 per share, resulting in a further reduction of the Note balance of $0.2 million, and the recognition of additional interest expense was immaterial. In October 2021, the Company entered into a financing agreement with First Insurance Funding in order to fund a portion of its insurance policies. The amount financed is $0.4 million, which incurs interest at an annual rate of 4.17%. The Company is required to make monthly payments of $45,000 from November 2021 through July 2022. The outstanding balance as of June 30, 2022 was $0.1 million. In October 2020, the Company entered into a finance agreement with First Insurance Funding in order to fund a portion of its insurance policies. The amount financed was $0.7 million and incurred interest at a rate of 3.60%. The Company was required to make monthly payments of $63,000 from November 2020 through July 2021. There was no outstanding balance as of June 30, 2022.

DEBT

DEBT	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
DEBT	CONVERTIBLE NOTES Convertible notes as of June 30, 2022 and December 31, 2021 were as follows (in thousands): June 30, 2022 December 31, 2021 Principal amount $ 2,120 $ 1,060 Less: Original issuance discount ("OID") (120) (60) Less: Debt issuance costs (275) (229) Net proceeds 1,725 771 Default premium 178 — Conversion of note into common shares (1,260) (230) Accretion of OID and amortization of debt issuance costs 309 71 Carrying amount $ 952 $ 612 On November 14, 2021, the Company entered into a securities purchase agreement (the “SPA”) with an institutional investor (the “Investor”) providing for the sale and issuance in series of registered direct offerings of senior convertible notes (“Notes”) in the aggregate original principal amount of up to $5.3 million (the “Offering”). On November 17, 2021, at the initial closing of this Offering, the Company sold and issued $1.06 million in aggregate principal amount of Notes to the Investor pursuant to a prospectus supplement to its effective shelf registration statement Form S-3 (Registration No. 333-237772) (the "Registration Statement"). The Notes have an OID of 6%, resulting in net proceeds to the Company of $1.0 million before other debt issuance costs, and mature on May 17, 2022. The Notes shall not bear interest except upon the occurrence of an event of default. After the occurrence of an event of default, the Notes will accrue interest at the rate of 15% per annum; provided, however, that in the event that such event of default is subsequently cured (and no other default then exists (including, without limitation, for the Company's failure to timely pay such interest at the default rate)), interest shall cease to accrue as of the calendar day immediately following the date of such cure. The Notes are senior to other indebtedness of the Company. The Notes have an initial fixed conversion price of $0.2611. The initial fixed conversion price is subject to proportional adjustment upon the occurrence of any stock split, stock dividend, stock combination and/or similar transactions and full-ratchet adjustment in connection with a subsequent offering at a per share price less than the fixed conversion price then in effect. Upon each additional closing, the fixed conversion price of all outstanding Notes is subject to downward adjustment if greater than the lower of (i) 120% of the closing bid price of the Company's common stock on the trading day immediately preceding such additional closing date; and (ii) 120% of the arithmetic average of the volume weighted average prices of the Company's common stock on the five trading days preceding the additional closing. The holder may convert any part of the Notes into shares of common stock at an “Alternate Conversion Price” equal to the lesser of (i) the fixed conversion price then in effect; (ii) the greater of the floor price of $0.01 and 90% of the arithmetic average of the three lowest daily volume weighted average prices of the Company's common stock during the ten trading days immediately prior to such conversion; and (iii) the greater of the floor price and 97% of the lowest sale price of the Company's common stock on the applicable conversion date. In connection with a change of control of the Company, each holder may require the Company to redeem in cash any portion of the Notes at the greater of the face value, a 15% redemption premium to the equity value of our common stock underlying the Notes and the equity value of the change of control consideration payable to the holder of common stock underlying the Notes. The equity value of our common stock underlying the Notes is calculated using the greatest closing sale price of Company common stock during the period immediately preceding the consummation or the public announcement of the change of control and ending the date the holder gives notice of such redemption. The equity value of the change of control consideration payable to the holder of common stock underlying the Notes is calculated using the aggregate cash consideration per share of common stock to be paid to the holders of common stock upon the change of control. If an event of default occurs, each holder may require the Company to redeem all or any portion of the Notes (including all accrued and unpaid interest and late charges thereon), in cash, at the greater of the face value and a 15% redemption premium or (10% if such event of default is a price default) to the greater of the face value and the equity value of the common stock underlying the Notes. The equity value of the common stock underlying the Notes is calculated using the greatest closing sale price of the common stock on any trading day immediately preceding such event of default and the date the entire payment is made. If the Company consummates a subsequent public or private offering of securities, each holder of Notes may require the Company to use up to 20% of the gross proceeds of such subsequent placement (less any reasonable placement agent, underwriter and/or legal fees and expenses) to redeem in cash all, or any portion, of the Notes, at a 5% redemption premium. The Company may redeem, at any time, any portion of the outstanding Notes in cash with a 15% redemption premium to the greater of the face value of the Notes or the equity value of its common stock. On March 25, 2022, the Company sold and issued an additional $1.06 million in principal amount of the Notes under this Offering (the "Second Tranche"), which Notes were offered pursuant to a prospectus supplement to the Registration Statement. The Notes issued in the Second Tranche also have an OID of 6%, resulting in net proceeds of the Company of $1.0 million, before other debt issuance costs. The Notes issued in the Second Tranche have the same material terms as those issued in the first tranche, but mature on September 25, 2022. The Notes issued in the second tranche have an initial conversion price of $0.1508, and pursuant to the Notes, upon closing of second tranche, the initial conversion price of the Notes issued in the first tranche in November 2021 was adjusted down from $0.2611 to $0.1508 as well. The Company did not repay the Notes issued in November in full on May 17, 2022, the maturity date, resulting in an event of default under such Notes. As a result of such default, the Notes issued in November, in the principal amount of $130,000 as of such date, began accruing interest at a rate of 15% per annum. Additionally, the default triggered the investor’s right under the Notes to require the Company to redeem all or any portion of the November Notes, in cash, at a price not less than the face value of such Notes plus a 15% redemption premium (the “Redemption Premium”). On May 18, 2022, the Company entered into a Forbearance Agreement with the investor, pursuant to which the investor agreed to forebear exercising any rights or remedies that it may have under the November Notes that arise as a result of the default until the earlier of (i) the date immediately prior to the date of occurrence of a Bankruptcy Event of Default (as defined in the Notes), (ii) the date of occurrence of any other event of default under Section 4(a) of the Notes, (iii) the time of any breach by the Company pursuant to the Forbearance Agreement, and (v) June 1, 2022 (such period, the “Forbearance Period”). In accordance with the Forbearance Agreement, the Company agreed to pay the investor the aggregate outstanding principal on the November Note at the Redemption Premium, including all accrued and unpaid interest, upon expiration of the Forbearance Period. As of May 31, 2022, prior to expiration of the Forbearance Period, the investor had converted the outstanding balance (including the redemption premium and accrued interest) due under the Notes issued in November, amounting to $151,772, into an aggregate of 3,751,971 shares of Company common stock at a conversion price of $0.04 per share. As a result, the Notes issued in November terminated. During the three and six months ended June 30, 2022, the volume weighted average price ("VWAP") of the Company's common stock was below $0.10 for more than 5 days, which constitutes a price default in accordance with the Notes. As a result, from the date of such default and for so long as such default remains uncured, the Notes that remain outstanding will accrue interest at a rate of 15% per annum. Following such default, the holder also added a 15% per annum default premium to the outstanding balance in accordance with the Notes. In addition, the holder now has the right to require the Company to redeem all or any portion of the Notes (including all accrued and unpaid interest and late charges thereon), in cash, at a price not less than the face value of the Notes and a 10% redemption premium, as determined in accordance with the terms of the Notes. The Company is in communications with the holder of the Notes regarding the default, and anticipates to come to a mutually agreeable resolution related thereto, although no assurances can be given. The Company recorded accrued interest of $29,000 as of June 30, 2022. There was no accrued interest as of December 31, 2021. During the three and six months ended June 30, 2022, holders of certain Notes converted amounts payable under such Notes into an aggregate of 7,172,244 and 13,976,525 shares of Company common stock at a weighted average conversion price of $0.05 and $0.07 per share, resulting in a reduction of the Note balance of $0.4 million and $1.0 million, respectively. In addition, the Company recognized additional interest expense associated with the conversion $0.6 million during the six months ended June 30, 2022. Additional interest expense for the three months ended June 30, 2022 were immaterial. Subsequent to June 30, 2022, holders of certain of the Notes converted amounts payable under such Notes into an additional 7,308,876 shares of Company common stock at a weighted average conversion price of $0.03 per share, resulting in a further reduction of the Note balance of $0.2 million, and the recognition of additional interest expense was immaterial. In October 2021, the Company entered into a financing agreement with First Insurance Funding in order to fund a portion of its insurance policies. The amount financed is $0.4 million, which incurs interest at an annual rate of 4.17%. The Company is required to make monthly payments of $45,000 from November 2021 through July 2022. The outstanding balance as of June 30, 2022 was $0.1 million. In October 2020, the Company entered into a finance agreement with First Insurance Funding in order to fund a portion of its insurance policies. The amount financed was $0.7 million and incurred interest at a rate of 3.60%. The Company was required to make monthly payments of $63,000 from November 2020 through July 2021. There was no outstanding balance as of June 30, 2022.

STOCKHOLDERS EQUITY

STOCKHOLDERS EQUITY	6 Months Ended
	Jun. 30, 2022
Stockholders' Equity Attributable to Parent [Abstract]
STOCKHOLDERS EQUITY	STOCKHOLDERS EQUITY Common Stock On December 8, 2020, the Company entered into a Common Stock Purchase Agreement (the "SPA") with Tumim Stone Capital, LLC ("Tumim") to issue and sell up to $10.0 million in shares of the Company's common stock. The SPA provided, among other things, that the Company may direct, every three trading days, Tumim to purchase a number of shares not to exceed an amount determined based upon the trading volume and stock price of the Company's shares. During the three and six months ended June 30, 2021, the Company sold 1,669,086 and 7,796,356 shares of common stock pursuant to the SPA, and recognized proceeds of $0.6 million and $3.9 million, respectively. The Company and Tumim mutually agreed to terminate the SPA, effective November 15, 2021. During the six months ended June 30, 2022, the Company issued 3,496,000 shares of common stock to a vendor as compensation for $0.4 million of services provided to the Company. On June 6, 2022, the Company filed a Certificate of Amendment to its Certificate of Incorporation with the Secretary of State of the State of Delaware, pursuant to which the number of shares of all classes of the Company’s capital stock authorized for issuance was increased from 200,000,000 shares to 800,000,000 shares, and the number of shares of common stock authorized for issuance was correspondingly increased from 190,000,000 shares to 790,000,000 shares. The number of shares of preferred stock authorized for issuance was not impacted by the amendment. Preferred Stock On March 30, 2022, the Company closed a registered direct offering with an institutional investor for the issuance and sale of an aggregate of 700 shares of the Company's Series A Preferred Stock ("Preferred Stock") and warrants to purchase up to an aggregate of 10,000,000 shares of common stock, par value $0.0001 per share, for gross proceeds of $0.7 million, or net cash proceeds of $0.6 million after deducting $0.1 million related to placement agent’s fees and other offering expenses. Shares of the Preferred Stock had a stated value of $1,000 per share and were convertible into an aggregate of 10,000,000 shares of common stock at a conversion price of $0.07 per share at any time. The warrants have an exercise price of $0.10 per share. In addition, the Company issued designees of the placement agent warrants to purchase up to 750,000 shares of common stock at an exercise price of $0.0875 per share, and their fair value of $0.1 million was recorded as an additional offering cost. In April 2022, the investor converted all of the 700 outstanding shares of Preferred Stock into an aggregate of 10,000,000 shares of common stock. The Company recognized a beneficial conversion charge of $0.9 million during the quarter ended June 30, 2022, which represents the in-the-money value of the conversion rate as of the date of conversion. The Preferred Stock did not have any mandatory redemption provisions, contingently redeemable redemption provisions, preferential dividend rights, or liquidation preferences. The Preferred Stock had no voting rights, other than the right to vote as a class on certain matters, except that each share of Preferred Stock had the right to cast 170,000 votes per share of Preferred Stock, voting together as a single class with holders of Company common stock, on the proposals to (i) amend the Company’s Certificate of Incorporation to increase the number of shares of capital stock authorized for issuance thereunder from 200,000,000 to 800,000,000 and the authorized number of shares of common stock from 190,000,000 to 790,000,000 shares (the “Increase in Authorized”), and (ii) authorize the Company’s board of directors, at any time or times before May 30, 2025, to amend the Company’s Certificate of Incorporation to effectuate a reverse stock split of the Company’s issued and outstanding shares of common stock in a range of not less than 1-for-10 and not greater than 1-for-400, which were presented to the Company’s shareholders for approval, and were ultimately approved by the Company's shareholders, at the Company’s 2022 annual meeting of shareholders. The Company evaluated the classification of the Preferred Stock and determined equity classification was appropriate due to no mandatory or contingently redeemable redemption features. The warrants issued to the investors in the offering were considered freestanding equity classified instruments. The Company first allocated gross proceeds from the registered direct offering between the Preferred Stock and the warrants issued to investors using a relative fair value approach, resulting in an initial allocation to the instruments of $0.4 million and $0.3 million, respectively. The issuance costs, inclusive of the fair value of the warrants issued to placement agent designees, were allocated between the Preferred Stock and the warrants issued to investors in a systematic and rational manner, resulting in an allocation to the instruments of $0.1 million and $0.1 million, for a net allocation of $0.3 million and $0.2 million, respectively. On the issuance date, the Company estimated the fair value of the warrants issued to investors and to placement agent designees using a Black-Scholes pricing model using the following assumptions: (i) contractual term of 3 years, (ii) expected volatility rate of 104.0%, (iii) risk-free interest rate of 2.5%, (iv) expected dividend rate of 0%, and (v) closing price of the Company’s common stock as of the day immediately preceding the registered direct offering. The fair value of Preferred Stock was estimated based upon equivalent common shares that Preferred Stock could have been converted into at the closing price of the day immediately preceding the purchase date. The embedded conversion feature was evaluated and bifurcation from the Preferred Stock equity host was not considered necessary. Warrants The following represents a summary of the warrants outstanding at each of the dates identified: Number of Shares Underlying Warrants Issue Date Classification Exercise Price Expiration Date June 30, 2022 December 31, 2021 March 30, 2022 Equity $ 0.1000 May 26, 2025 10,000,000 — March 30, 2022 Equity $ 0.0875 May 26, 2025 750,000 — 10,750,000 —

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION As of December 31, 2021, there were 38,976,000 shares of Company common stock authorized for issuance under the CV Sciences, Inc. Amended and Restated 2013 Equity Incentive Plan (the "2013 Plan"). On June 11, 2019, the Company’s stockholders approved an amendment to the 2013 Plan to add an automatic “evergreen” provision regarding the number of shares to be annually added to the 2013 Plan. As a result, the number of shares of common stock that will be automatically added to the 2013 Plan on January 1st of each year during the term of the plan, starting with January 1, 2020, will be the lesser of: (a) 4% of the total shares of the Company’s common stock outstanding on December 31st of the prior year, (b) 4,000,000 shares of the Company’s common stock, or (c) a lesser number of shares of the Company’s common stock as determined by the Company’s Board of Directors. On January 1, 2022, the Company's Board of Directors elected not to add any shares to the 2013 Plan. In March 2022, the Company cancelled 9,000,000 outstanding stock options, of which 7,000,000 were previously granted under the 2013 Plan. On March 30, 2022, the Company's Board of Directors approved, and the Company adopted, an amendment to the 2013 Plan to reduce the number of shares available for issuance under the 2013 Plan by 8,000,000 shares. As of June 30, 2022, the Company had 4,993,000 authorized but unissued shares reserved and available for issuance under the 2013 Plan. As of June 30, 2022, total unrecognized compensation cost related to non-vested stock-based compensation arrangements was $0.6 million, which is expected to be recognized over a weighted-average period of 0.66 years. The following summarizes activity related to the Company's stock options (in thousands, except per share data): Number of Shares Weighted Average Weighted Average Aggregate Intrinsic Value Outstanding - December 31, 2021 30,163 $ 0.49 5.5 $ — Granted — — — — Exercised — — — — Forfeited (8,517) 0.50 — — Outstanding - June 30, 2022 21,646 0.49 3.6 — Exercisable - June 30, 2022 19,120 0.50 3.9 — Vested or expected to vest - June 30, 2022 21,646 $ 0.49 3.6 $ — The Company has established performance milestones in connection with drug development efforts for its lead drug candidate CVSI-007. The above table includes 4,250,000 vested performance-based options as of June 30, 2022, which were issued to Michael Mona Jr. ("Mona Jr.") outside of the 2013 Plan. As of June 30, 2022, there were 6,750,000 remaining unvested stock options granted to Mona Jr. outside of the 2013 Plan which are not included in the above table. These stock options vest upon the completion of future performance conditions (refer to Note 12). There were no stock options exercised during the six months ended June 30, 2022. The intrinsic value of stock option exercises during the six months ended June 30, 2021 was not material. The following table presents the weighted average grant date fair value of stock options granted and the weighted-average assumptions used to estimate the fair value on the date of grant using the Black-Scholes valuation model: Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Volatility * 132.1% * 133.7% Risk-Free Interest Rate * 0.8% * 0.9% Expected Term (in years) * 5.49 * 5.61 Dividend Rate * —% * —% Fair Value Per Share on Grant Date * $0.32 * $0.49 * There were no grants during the three and six months ended June 30, 2022. The risk-free interest rates are based on the implied yield available on U.S. Treasury constant maturities with remaining terms equivalent to the respective expected terms of the options. Expected volatility is based on the historical volatility of the Company's common stock. The Company estimates the expected term for stock options awarded to employees, officers and directors using the simplified method in accordance with ASC Topic 718, Stock Compensation, because the Company does not have sufficient relevant historical information to develop reasonable expectations about future exercise patterns. In the future, as the Company gains historical data for the actual term over which stock options are held, the expected term may change, which could substantially change the grant-date fair value of future stock option awards, and, consequently, compensation of future grants.

NET LOSS PER SHARE

NET LOSS PER SHARE	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
NET LOSS PER SHARE	NET LOSS PER SHARENet loss per common share is computed using the two-class method, which is required due to the participating nature of the Preferred Stock (as defined and discussed in Note 6). Except with respect to voting and conversion rights, the rights of the holders of the Company’s common stock and the Preferred Stock are identical. Each class of shares has the same rights to dividends. Although the Preferred Stock are participating securities, such securities do not participate in net losses, and therefore, do not impact the Company’s net loss per share calculation as of June 30, 2022. The Company computes basic net loss per share using the weighted-average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted-average number of common shares plus potential common shares. The Company's stock options, including those with performance conditions, are included in the calculation of diluted net loss per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net loss per share when their effect is anti-dilutive. The following common stock equivalents were not included in the calculation of net loss per diluted share because their effect were anti-dilutive (in thousands): Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Stock options 17,396 26,333 17,396 26,333 Performance stock options 11,000 13,000 11,000 13,000 Warrants 10,750 — 10,750 — Convertible notes 6,887 — 6,887 — Total 46,033 39,333 46,033 39,333

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES On March 17, 2015, Michael Ruth filed a shareholder derivative suit in Nevada District Court alleging breach of fiduciary duty and gross mismanagement (the “Ruth Complaint”). The claims are premised on the same events that were the subject of a purported class action filed in the Southern District of New York on April 23, 2014 (the “Sallustro Case”). On July 2, 2019, the court in the Sallustro Case entered a final order dismissing the complaint with prejudice. The Company did not make any settlement payment, and at no time was there a finding of wrongdoing by the Company or any of its directors. Regarding the Ruth Complaint, the parties previously agreed to stay the action pending the conclusion of discovery in the Sallustro Case. Now that the Sallustro Case has been dismissed, the stay has been lifted. Plaintiff’s counsel recently informed the Court that Mr. Ruth sold his shares of CVSI stock and thus he no longer has standing to pursue this claim. However, the Court allowed Plaintiff’s counsel to substitute CVSI shareholder Otilda Lamont as the named plaintiff. On September 20, 2019, defendants filed a motion to dismiss the Ruth Complaint and the Court issued a ruling denying the motion to dismiss on November 24, 2020. A Third Amended Complaint was filed on December 11, 2020 substituting Otilda Lamont as plaintiff. Defendants filed an answer to the Ruth Complaint on January 11, 2021, and discovery is ongoing. The Court issued a schedule whereby discovery ended on November 19, 2021. Management intends to vigorously defend the allegations. On August 24, 2018, David Smith filed a purported class action complaint in Nevada District Court (the "Smith Complaint") alleging certain misstatements in the Company's public filings that led to stock price fluctuations and financial harm. Several additional individuals filed similar claims, and the Smith Complaint and each of the other suits all arise out of a report published by Citron Research on Twitter on August 20, 2018, suggesting that the Company misled investors by failing to disclose that the Company’s efforts to secure patent protection for CVSI-007 had been “finally rejected” by the United States Patent and Trademark Office ("USPTO"). On November 15, 2018, the court consolidated the actions and appointed Richard Ina, Trustee for the Ina Family Trust, as Lead Plaintiff for the consolidated actions. On January 4, 2019, Counsel for Lead Plaintiff Richard Ina, Trustee for the Ina Family Trust, filed a “consolidated amended complaint”. On March 5, 2019, defendants filed a motion to dismiss the action. The Court denied the motion to dismiss on December 10, 2019, and the parties commenced discovery in the action. Recently, the parties attended mediation and reached a preliminary settlement to resolve this matter for a total of $712,500. The settlement payment was paid through insurance. On March 9, 2022, the Nevada District Court issued an order granting preliminary approval of the settlement. On July 22, 2022, the Nevada District Court issued an order granting final approval of the settlement. The case has now been dismissed. Arising out of the same facts and circumstances in the Smith Complaint, on June 11, 2020, Phillip Berry filed a derivative suit in the United States District Court for the Southern District of California alleging breaches of fiduciary duty against the Company and various defendants, and waste of corporate assets (the “Berry Complaint”). Defendants filed a motion to dismiss. On May 14, 2021, the District Court issued an order denying the motion to dismiss without prejudice but staying the action pending resolution of the Ina case. In addition to the Berry Complaint, five additional shareholder derivative suits have been filed which are premised on the same event as the Smith Complaint. This includes the most recent shareholder derivative action filed on April 13, 2021 by David Menna in the Superior Court of the State of California, County of San Diego. On May 19, 2020, the USPTO issued a patent pertaining to CVSI-007, which the Company believes negates and defeats any claims that the Company and the various defendants misled the market by not disclosing that the USPTO had finally rejected the patent. On July 28, 2022, the Company and the individual defendants involved in the case involving the Berry Complaint executed a global settlement agreement for the resolution of this action and the five other pending related shareholder derivative actions concerning the same underlying facts, pursuant to which neither the Company nor the individual defendants will pay any damages. The settlement agreement contemplates the implementation by the Company of certain corporate reforms and payment of the plaintiffs’ total attorneys’ fees in the six related derivative actions, amounting to an aggregate of $275,000. On July 29, 2022, the parties submitted the settlement agreement for approval by the judge overseeing the first-filed of the six shareholder derivative actions, who set a hearing to determine whether to preliminarily approve the settlement agreement for September 15, 2022. The parties intend to seek stays of the five other pending shareholder derivative actions pending the court’s determination whether to approve the settlement agreement. The Company anticipates that all settlement payments will be paid through insurance. On December 3, 2019, Michelene Colette and Leticia Shaw filed a putative class action complaint in the Central District of California, alleging the labeling on the Company’s products violated the Food, Drug, and Cosmetic Act of 1938 (the “Colette Complaint”). On February 6, 2020, the Company filed a motion to dismiss the Colette Complaint. Instead of opposing our motion, plaintiffs elected to file an amended complaint on February 25, 2020. On March 11, 2020, we filed a motion to dismiss the amended complaint. The court issued a ruling on May 22, 2020 that stayed this proceeding in its entirety and dismissed part of the amended complaint. The portion of the proceeding that is stayed will remain stayed until the U.S. Food and Drug Administration promulgates rules that govern cannabidiol products (the “FDA Rules”). When such FDA Rules are promulgated, the plaintiffs will be allowed to ask the court to reopen the proceeding. Management intends to vigorously defend the allegations. On July 22, 2020, the Company filed a complaint in the San Diego Superior Court for declaratory relief to confirm the rescission of Mona Jr.’s employment agreement, which terminated certain severance and other post-termination compensation and benefits, as well as to recover amounts owed to the Company by Mona Jr. in connection with his purchase of a personal seat license ("PSL") for the Raiders Stadium and certain advance payments made on Mona Jr.’s behalf. The case was moved to an arbitration before the American Arbitration Association pursuant to the arbitration agreement in Mona Jr.'s employment agreement. Mona Jr. is seeking to obtain the terminated severance and other post-termination compensation and benefits under his employment agreement and reimbursement of legal fees associated with this action. On April 27, 2022, the arbitrator issued a final ruling awarding the Company amounts owed by Mona Jr. related to his purchase of the PSL and other advance payments made on Mona Jr.'s behalf for a total of $0.3 million, including prejudgment interest. The arbitrator also awarded Mona Jr. termination severance and other post-termination compensation and benefits under his employment agreement for a total of $0.6 million, including prejudgment interest. The net amount due to Mona Jr. of $0.3 million was paid to Mona Jr., net of applicable payroll taxes during the three months ended June 30, 2022. On November 5, 2021, Mona Jr. filed a complaint against the Company in Nevada state court seeking to recover federal and state taxes from the Company associated with the RSU release in 2019 - refer also to Note 12. Related Parties, for further information. On December 22, 2021, the Company filed a motion to dismiss the complaint. The motion to dismiss is fully briefed and is pending before the court. Management intends to vigorously defend the allegations. In the normal course of business, the Company is a party to a variety of agreements pursuant to which they may be obligated to indemnify the other party. It is not possible to predict the maximum potential amount of future payments under these types of agreements due to the conditional nature of our obligations, and the unique facts and circumstances involved in each particular agreement. Historically, payments made by us under these types of agreements have not had a material effect on our business, results of operations or financial condition.

SEGMENT INFORMATION

SEGMENT INFORMATION	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATIONThe Company operates in two distinct business segments: (i) a consumer products segment in developing, manufacturing, marketing and selling hemp extracts and other proven science-backed, natural ingredients and products to a range of market sectors; and (ii) a specialty pharmaceutical segment focused on developing and commercializing novel therapeutics utilizing CBD. The Company’s segments maintain separate financial information for which operating results are evaluated on a regular basis by the Company’s senior management in deciding how to allocate resources and in assessing performance. The Company evaluates its consumer products segment based on net product sales, gross profit and operating income or loss. The Company currently evaluates its specialty pharmaceutical segment based on the progress of its clinical development programs. The following table presents information by reportable operating segment for the three and six months ended June 30, 2022 and 2021 (in thousands): Consumer Products Specialty Pharmaceutical Segment Consolidated Totals Three months ended June 30, 2022: Product sales, net $ 4,138 $ — $ 4,138 Gross profit $ 1,270 $ — $ 1,270 Research and development expense 84 18 102 Selling, general and administrative expense 3,474 9 3,483 Operating loss $ (2,288) $ (27) $ (2,315) Three months ended June 30, 2021: Product sales, net $ 5,128 $ — $ 5,128 Gross profit $ 2,290 $ — $ 2,290 Research and development expense 126 99 225 Selling, general and administrative expense 5,565 10 5,575 Operating loss $ (3,401) $ (109) $ (3,510) Consumer Products Specialty Pharmaceutical Segment Consolidated Totals Six months ended June 30, 2022: Product sales, net $ 8,585 $ — $ 8,585 Gross profit $ 2,426 $ — $ 2,426 Research and development expense 201 22 223 Selling, general and administrative expense 5,993 40 6,033 Operating loss $ (3,768) $ (62) $ (3,830) Six months ended June 30, 2021: Product sales, net $ 9,972 $ — $ 9,972 Gross profit $ 4,648 $ — $ 4,648 Research and development expense 254 157 411 Selling, general and administrative expense 10,835 25 $ 10,860 Operating loss $ (6,441) $ (182) $ (6,623)

INCOME TAXES

INCOME TAXES	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXESFor the three and six months ended June 30, 2022 and 2021, the Company generated a net loss for which no tax benefit has been recognized due to uncertainties regarding the future realization of the tax benefit. The tax effects of the net loss will be recognized when realization of the tax benefit becomes more likely than not or the tax effects of the previous interim losses are utilized.

RELATED PARTIES

RELATED PARTIES	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
RELATED PARTIES	RELATED PARTIES During the year ended December 31, 2019, the Company's former President and Chief Executive Officer, Mona Jr., and the Company entered into a Settlement Agreement (the “Settlement Agreement”), pursuant to which the Company agreed that Mona Jr.’s resignation from the Company on January 22, 2019 was for Good Reason (as defined in Mona Jr.’s Employment Agreement) and agreed to extend the deadline for Mona Jr.’s exercise of his stock options for a period of five years. As of June 30, 2022, Mona Jr. has 11,300,000 fully vested outstanding stock options with a weighted average exercise price of $0.42 per share. In exchange, Mona Jr. agreed that notwithstanding the terms of his Employment Agreement providing for acceleration of vesting of all stock options and RSU's upon a Good Reason resignation, certain of his unvested stock options would not immediately vest, but rather continue to vest if, and only if, certain Company milestones are achieved related to the Company’s drug development efforts. These stock options were issued in July 2016 (6,000,000 options) and March 2017 (5,000,000 options), and 6,750,000 of these stock options have not vested as of June 30, 2022. The Company and Mona Jr. also agreed to mutually release all claims arising out of and related to Mona Jr.’s resignation and separation from the Company. As a result of the Settlement Agreement, the Company recorded stock-based compensation expense related to the accelerated vesting of the RSU's of $5.1 million and the modification of certain stock options of $2.7 million during the year ended December 31, 2019. Under Mona Jr.'s Employment Agreement, the 2,950,000 RSU's that were issued to Mona Jr. became vested as a result of the Company's agreement that his resignation from the Company was for Good Reason. The vesting of the RSU's resulted in taxable compensation to Mona Jr. and thus was subject to income tax withholdings. No amounts were withheld (either in cash or the equivalent of shares of common stock from the vesting of the RSU's) or included in the original Company’s payroll tax filing. The compensation is subject to Federal and State income tax withholding and Federal Insurance Contributions Act (“FICA”) taxes withholding estimated to be $6.4 million for the employee portions. The employer portion of the FICA taxes is $0.2 million and has been recorded as a component of selling, general and administrative expenses during the year ended December 31, 2019. During the year ended December 31, 2020, the Company reported the taxable compensation associated with the RSU release to the taxing authorities and included the amount in Mona Jr.'s W-2 for 2019. In addition, the Company paid the employer and employee portion of the FICA taxes of $0.2 million, respectively. Although the primary tax liability is the responsibility of the employee, the Company is secondarily liable and thus has recorded the liability on its condensed balance sheet as of December 31, 2020 in an amount of $6.2 million which was recorded as a component of accrued expenses. The Company initially recorded an offsetting receivable of $6.2 million during the second quarter of 2019 for the total estimated Federal and State income taxes which should have been withheld in addition to the employee portion of the FICA payroll taxes as the primary liability is ultimately the responsibility of the employee. The receivable was recorded as a component of prepaid expense and other on the condensed balance sheet. The deadline to file and pay personal income taxes for 2019 was on October 15, 2020. To date, notwithstanding repeated requests from the Company, Mona Jr. has not provided to the Company the appropriate documentation substantiating that he properly filed and paid his taxes for 2019. As a result, the Company derecognized its previously recorded receivable of $6.2 million during the fourth quarter of 2020. The associated liability may be relieved once the tax amount is paid by Mona Jr. and the Company has received the required taxing authority documentation from Mona Jr. If the tax amount is not paid by Mona Jr., the Company would be liable for such withholding tax due. Additionally, the Company could be subject to penalties if the amounts are ultimately not paid. The Company does not believe that any such penalties are probable or reasonably possible as of June 30, 2022. On July 22, 2020, the Company filed a complaint in the San Diego Superior Court for declaratory relief to confirm the rescission of Mona Jr.'s Employment Agreement, which terminated certain severance and other post-termination compensation and benefits, and to recover amounts owed to the Company by Mona Jr. in connection with his purchase of personal seat licenses for the Raiders stadium and certain advance payments made on Mona Jr.'s behalf - refer also to Note 9. Commitments and Contingencies,

ORGANIZATION AND BUSINESS (Poli

ORGANIZATION AND BUSINESS (Policies)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation - The unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States ("U.S. GAAP") for interim financial information and the instructions to Rule 10-01 of Regulation S-X. Accordingly, they do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, the interim financial information includes all normal recurring adjustments necessary for a fair statement of the results for the interim periods. These condensed financial statements are unaudited and should be read in conjunction with the Company's Annual Report on Form 10-K for its fiscal year ended December 31, 2021. Operating results for interim periods are not necessarily indicative of operating results for an entire fiscal year. Liquidity Considerations – U.S. GAAP requires management to assess a company's ability to continue as a going concern within one year from the financial statement issuance and to provide related note disclosure in certain circumstances. The accompanying financial statements and notes have been prepared assuming the Company will continue as a going concern. For the six months ended June 30, 2022 and the year ended December 31, 2021, the Company generated negative cash flows from operations of $1.5 million and $7.5 million, respectively. In addition, the Company had an accumulated deficit of $84.3 million as of June 30, 2022. Management anticipates that the Company will be dependent, for the near future, on additional investment capital to fund operations, growth initiatives and to continue to make and implement strategic cost reductions, including reductions in employee headcount, vendor spending, and delaying expenses related to its drug development activities. The Company intends to position itself so that it will be able to raise additional funds through the capital markets, issuance of debt, and/or securing lines of credit. In March 2022, the Company closed a second tranche of its convertible note offering and a convertible preferred stock financing, which resulted in gross proceeds to the Company before closing expenses of approximately $1.0 million and $0.7 million, respectively. Under the provisions of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) signed into law on March 27, 2020 and the subsequent extension of the CARES Act, the Company was eligible for a refundable employee retention credit subject to certain criteria. The Company determined that it qualifies for the tax credit under the CARES Act. In March 2022, the Company claimed employee retention credits, which are recognized as a reduction to general and administrative expenses of $2.0 million during the six months ended June 30, 2022. The amount is included in prepaid expenses and other in the Company's condensed balance sheet as of June 30, 2022. The Company's operating results and accumulated deficit, amongst other factors, raise substantial doubt about the Company's ability to continue as a going concern. The Company will continue to pursue the actions outlined above, as well as work towards increasing revenue and operating cash flows to meet its future liquidity requirements. However, there can be no assurance that the Company will be successful in any capital-raising efforts that it may undertake, and the failure of the Company to raise additional capital could adversely affect its future operations and viability.
Use of Estimates	Use of Estimates - The preparation of the condensed financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the condensed financial statements and
Fair Value Measurements	Fair Value Measurements - Fair value is defined as the price that would be received from the sale of an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The carrying values of accounts receivable, other current assets, accounts payable, and certain accrued expenses as of June 30, 2022 and December 31, 2021, approximate their fair value due to the short-term nature of these items. The Company's debt balance also approximates fair value as of June 30, 2022 and December 31, 2021, as the interest rate on the debt approximates the rates available to the Company as of such dates. The estimated fair value for the convertible notes payable is not readily determinable because of the numerous provisions in the notes, including conversion terms. The accounting guidance establishes a three-level hierarchy for disclosure that is based on the extent and level of judgment used to estimate the fair value of assets and liabilities. • Level 1 - uses unadjusted quoted prices that are available in active markets for identical assets or liabilities. The Company does not have any assets or liabilities that are valued using inputs identified under a Level 1 hierarchy as of June 30, 2022 and December 31, 2021. • Level 2 - uses inputs other than quoted prices included in Level 1 that are either directly or indirectly observable through correlation with market data. These include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; and inputs to valuation models or other pricing methodologies that do not require significant judgment because the inputs used in the model, such as interest rates and volatility, can be corroborated by readily observable market data. The Company did not have any assets or liabilities that are valued using inputs identified under a Level 2 hierarchy as of June 30, 2022 and December 31, 2021. • Level 3 - uses one or more significant inputs that are unobservable and supported by little or no market activity, and that reflect the use of significant management judgment. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques, and significant management judgment or estimation. The Company did not have any assets or liabilities that are valued using inputs identified under a Level 3 hierarchy as of June 30, 2022 and December 31, 2021.
Recent Accounting Pronouncements Not Yet Adopted and Recent Adopted Pronouncements	Recent Accounting Pronouncements Not Yet Adopted In June 2016, the Financial Accounting Standards Board ("FASB") issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments and subsequent amendments to the initial guidance: ASU 2018-19, ASU 2019-04 and ASU 2019-05 (collectively, “Topic 326”). Topic 326 requires measurement and recognition of expected credit losses for financial assets held. Topic 326 was to be effective for reporting periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates, which deferred the effective dates for the Company, as a smaller reporting company, until fiscal year 2023. The Company currently plans to adopt the aforementioned guidance at the beginning of fiscal 2023. The Company is currently evaluating the potential impact of Topic 326 on the Company’s condensed financial statements. Recent Adopted Pronouncements In August 2020, the FASB issued ASU No. 2020-06, “Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity,” or ASU 2020-06. ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by reducing the number of accounting models and limiting the number of embedded conversion features separately recognized from the primary contract. The guidance also includes targeted improvements to the disclosures for convertible instruments and earnings per share. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023, including interim periods within those fiscal years and early adoption is permitted in annual reporting periods ending after December 15, 2020. The Company adopted this guidance as of January 1, 2021, using the full retrospective method of adoption. Adoption of this guidance eliminated the presentation of the beneficial conversion feature on the statement of operations, delayed recognition of beneficial conversion amounts until they are triggered, and had no other material impact on the Company.

ORGANIZATION AND BUSINESS (Tabl

ORGANIZATION AND BUSINESS (Tables)	6 Months Ended
	Jun. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Cash, Cash Equivalents	The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheets to the total of the same amounts shown in the statement of cash flows for the six months ended June 30, 2022 and 2021 (in thousands): June 30, June 30, Cash and cash equivalents $ 1,114 $ 2,460 Restricted cash — 501 Total cash, cash equivalents and restricted cash shown in the statements of cash flows $ 1,114 $ 2,961
Schedule of Restricted Cash	The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheets to the total of the same amounts shown in the statement of cash flows for the six months ended June 30, 2022 and 2021 (in thousands): June 30, June 30, Cash and cash equivalents $ 1,114 $ 2,460 Restricted cash — 501 Total cash, cash equivalents and restricted cash shown in the statements of cash flows $ 1,114 $ 2,961
Revenue Product Sales by Channel	The following presents product sales by retail (B2B) and e-commerce (B2C) channels for the three and six months ended June 30, 2022 and 2021: Three months ended June 30, 2022 Three months ended June 30, 2021 Amount % of product sales, net Amount % of product sales, net (in thousands) (in thousands) Retail sales (B2B) $ 2,292 55.4 % $ 3,235 63.1 % E-Commerce sales (B2C) 1,846 44.6 % 1,893 36.9 % Product sales, net $ 4,138 100.0 % $ 5,128 100.0 % Six months ended June 30, 2022 Six months ended June 30, 2021 Amount % of product sales, net Amount % of product sales, net (in thousands) (in thousands) Retail sales (B2B) $ 4,851 56.5 % $ 6,210 62.3 % E-Commerce sales (B2C) 3,734 43.5 % 3,762 37.7 % Product sales, net $ 8,585 100.0 % $ 9,972 100.0 %

BALANCE SHEET DETAILS (Tables)

BALANCE SHEET DETAILS (Tables)	6 Months Ended
	Jun. 30, 2022
Condensed Financial Information Disclosure [Abstract]
Schedule of Inventory	Inventory as of June 30, 2022 and December 31, 2021 was comprised of the following (in thousands): June 30, December 31, Raw materials $ 3,635 $ 4,023 Work in process 1,605 1,286 Finished goods 2,117 3,315 $ 7,357 $ 8,624
Schedule of Accrued Expenses	Accrued expenses Accrued expenses as of June 30, 2022 and December 31, 2021 were as follows (in thousands): June 30, December 31, Accrued payroll expenses (1) $ 8,450 $ 9,023 Other accrued liabilities 1,481 1,892 $ 9,931 $ 10,915 (1) This includes a $6.7 million tax liability associated with a related party transaction, as discussed in Note 12.

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Lease Information	Information related to the Company's operating lease assets and related lease liabilities were as follows: June 30, 2022 Remaining lease term (in months) 35 Discount rate 7.0 %
Maturities of lease liabilities	Maturities of lease liabilities as of June 30, 2022 were as follows (in thousands): Year ending December 31, 2022 (remaining six months) $ 66 2023 135 2024 139 2025 60 400 Less imputed interest (40) Total lease liabilities $ 360 Current operating lease liabilities $ 111 Non-current operating lease liabilities 249 Total lease liabilities $ 360

CONVERTIBLE NOTES (Tables)

CONVERTIBLE NOTES (Tables)	6 Months Ended
	Jun. 30, 2022
Debt Disclosure [Abstract]
Schedule of Convertible Debt	Convertible notes as of June 30, 2022 and December 31, 2021 were as follows (in thousands): June 30, 2022 December 31, 2021 Principal amount $ 2,120 $ 1,060 Less: Original issuance discount ("OID") (120) (60) Less: Debt issuance costs (275) (229) Net proceeds 1,725 771 Default premium 178 — Conversion of note into common shares (1,260) (230) Accretion of OID and amortization of debt issuance costs 309 71 Carrying amount $ 952 $ 612

STOCKHOLDERS EQUITY (Tables)

STOCKHOLDERS EQUITY (Tables)	6 Months Ended
	Jun. 30, 2022
Stockholders' Equity Attributable to Parent [Abstract]
Schedule of Warrants Outstanding	The following represents a summary of the warrants outstanding at each of the dates identified: Number of Shares Underlying Warrants Issue Date Classification Exercise Price Expiration Date June 30, 2022 December 31, 2021 March 30, 2022 Equity $ 0.1000 May 26, 2025 10,000,000 — March 30, 2022 Equity $ 0.0875 May 26, 2025 750,000 — 10,750,000 —

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	6 Months Ended
	Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock Option Activity	The following summarizes activity related to the Company's stock options (in thousands, except per share data): Number of Shares Weighted Average Weighted Average Aggregate Intrinsic Value Outstanding - December 31, 2021 30,163 $ 0.49 5.5 $ — Granted — — — — Exercised — — — — Forfeited (8,517) 0.50 — — Outstanding - June 30, 2022 21,646 0.49 3.6 — Exercisable - June 30, 2022 19,120 0.50 3.9 — Vested or expected to vest - June 30, 2022 21,646 $ 0.49 3.6 $ —
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The following table presents the weighted average grant date fair value of stock options granted and the weighted-average assumptions used to estimate the fair value on the date of grant using the Black-Scholes valuation model: Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Volatility * 132.1% * 133.7% Risk-Free Interest Rate * 0.8% * 0.9% Expected Term (in years) * 5.49 * 5.61 Dividend Rate * —% * —% Fair Value Per Share on Grant Date * $0.32 * $0.49 * There were no grants during the three and six months ended June 30, 2022.

NET LOSS PER SHARE (Tables)

NET LOSS PER SHARE (Tables)	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following common stock equivalents were not included in the calculation of net loss per diluted share because their effect were anti-dilutive (in thousands): Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Stock options 17,396 26,333 17,396 26,333 Performance stock options 11,000 13,000 11,000 13,000 Warrants 10,750 — 10,750 — Convertible notes 6,887 — 6,887 — Total 46,033 39,333 46,033 39,333

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Schedule of Segment Reporting Information	The following table presents information by reportable operating segment for the three and six months ended June 30, 2022 and 2021 (in thousands): Consumer Products Specialty Pharmaceutical Segment Consolidated Totals Three months ended June 30, 2022: Product sales, net $ 4,138 $ — $ 4,138 Gross profit $ 1,270 $ — $ 1,270 Research and development expense 84 18 102 Selling, general and administrative expense 3,474 9 3,483 Operating loss $ (2,288) $ (27) $ (2,315) Three months ended June 30, 2021: Product sales, net $ 5,128 $ — $ 5,128 Gross profit $ 2,290 $ — $ 2,290 Research and development expense 126 99 225 Selling, general and administrative expense 5,565 10 5,575 Operating loss $ (3,401) $ (109) $ (3,510) Consumer Products Specialty Pharmaceutical Segment Consolidated Totals Six months ended June 30, 2022: Product sales, net $ 8,585 $ — $ 8,585 Gross profit $ 2,426 $ — $ 2,426 Research and development expense 201 22 223 Selling, general and administrative expense 5,993 40 6,033 Operating loss $ (3,768) $ (62) $ (3,830) Six months ended June 30, 2021: Product sales, net $ 9,972 $ — $ 9,972 Gross profit $ 4,648 $ — $ 4,648 Research and development expense 254 157 411 Selling, general and administrative expense 10,835 25 $ 10,860 Operating loss $ (6,441) $ (182) $ (6,623)

ORGANIZATION AND BUSINESS - Nar

ORGANIZATION AND BUSINESS - Narrative (Details)		1 Months Ended	6 Months Ended		12 Months Ended
	Mar. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Jun. 30, 2022 USD ($) segment	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Number of operating segments | segment			2
Assets			$ 0		$ 0
Useful life			5 years
Negative operating cash flow			$ 1,548,000	$ 4,753,000	7,500,000
Retained earnings (accumulated deficit)			(84,345,000)		(79,475,000)
Proceeds from issuance of preferred stock	$ 700,000	$ 700,000
CARES Act, tax credit received under relief provision			2,000,000
Convertible Debt Due 2022 | Convertible Debt
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Proceeds from debt		$ 1,000,000
Level 1
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Liabilities			0		0
Level 2
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Assets			0		0
Liabilities			0		0
Level 3
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Assets			0		0
Liabilities			$ 0		$ 0

ORGANIZATION AND BUSINESS - Cas

ORGANIZATION AND BUSINESS - Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 1,114	$ 1,375	$ 2,460
Restricted cash	0		501
Total cash, cash equivalents and restricted cash shown in the statements of cash flows	$ 1,114	$ 1,375	$ 2,961	$ 4,525

ORGANIZATION AND BUSINESS - Rev

ORGANIZATION AND BUSINESS - Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of Revenue [Line Items]
Product sales, net	$ 4,138	$ 5,128	$ 8,585	$ 9,972
Concentration Risk, Product | Revenue Benchmark
Disaggregation of Revenue [Line Items]
% of product sales, net	100%	100%	100%	100%
Retail sales (B2B)
Disaggregation of Revenue [Line Items]
Product sales, net	$ 2,292	$ 3,235	$ 4,851	$ 6,210
Retail sales (B2B) | Concentration Risk, Product | Revenue Benchmark
Disaggregation of Revenue [Line Items]
% of product sales, net	55.40%	63.10%	56.50%	62.30%
E-Commerce sales (B2C)
Disaggregation of Revenue [Line Items]
Product sales, net	$ 1,846	$ 1,893	$ 3,734	$ 3,762
E-Commerce sales (B2C) | Concentration Risk, Product | Revenue Benchmark
Disaggregation of Revenue [Line Items]
% of product sales, net	44.60%	36.90%	43.50%	37.70%

BALANCE SHEET DETAILS - Invento

BALANCE SHEET DETAILS - Inventory (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Condensed Financial Information Disclosure [Abstract]
Raw materials	$ 3,635		$ 3,635		$ 4,023
Work in process	1,605		1,605		1,286
Finished goods	2,117		2,117		3,315
Inventory	7,357		7,357		$ 8,624
Inventory write-downs	$ 100	$ 100	$ 200	$ 100

BALANCE SHEET DETAILS - Intangi

BALANCE SHEET DETAILS - Intangibles, net (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Indefinite-lived Intangible Assets [Line Items]
Intangibles	$ 1,485	$ 1,485
In-Process Research and Development
Indefinite-lived Intangible Assets [Line Items]
Intangibles	$ 1,500	$ 1,500

BALANCE SHEET DETAILS - Accrued

BALANCE SHEET DETAILS - Accrued Expenses (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Condensed Balance Sheet Statements, Captions [Line Items]
Accrued payroll expenses	$ 8,450	$ 9,023
Other accrued liabilities	1,481	1,892
Total accrued expenses	9,931	10,915
Tax Liability
Condensed Balance Sheet Statements, Captions [Line Items]
Accrued payroll expenses	$ 6,700	$ 6,700

LEASES - Narrative (Details)

LEASES - Narrative (Details) ft² in Thousands, $ in Thousands	2 Months Ended	3 Months Ended		6 Months Ended
	Jul. 31, 2022 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	May 01, 2022 USD ($)	Apr. 30, 2022 USD ($) ft²	Dec. 31, 2021 USD ($)	Jul. 12, 2021 USD ($)
Lessee, Lease, Description [Line Items]
Lease liabilities for operating leases		$ 360		$ 360	$ 400
Right of use assets		326		326	$ 300		$ 0
Lease cost		0		0
Remaining lease obligations		$ 40		$ 40
Terminated San Diego Facility
Lessee, Lease, Description [Line Items]
Area of property leased | ft²						6
Lease term						3 years
Lease liabilities for operating leases						$ 400
Terminated San Diego Facility | Lease Termination
Lessee, Lease, Description [Line Items]
Lease liabilities for operating leases								$ 3,800
Remaining lease obligations								100
Operating lease, right-of-use asset, termination adjustment								$ 2,800
Gain on termination of lease			$ 900
Terminated San Diego Facility | Lease Termination | Subsequent Event
Lessee, Lease, Description [Line Items]
Base rent reimbursement	$ 100

LEASES -Information Related to

LEASES -Information Related to Operating Lease (Details)	Jun. 30, 2022
Leases [Abstract]
Weighted average remaining lease term (in months)	35 months
Weighted average discount rate	7%

LEASES - Maturity of Lease Liab

LEASES - Maturity of Lease Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	May 01, 2022	Dec. 31, 2021
Leases [Abstract]
2022 (remaining six months)	$ 66
2023	135
2024	139
2025	60
Total lease payments due	400
Less imputed interest	(40)
Total lease liabilities	360	$ 400
Current operating lease liabilities	111		$ 0
Non-current operating lease liabilities	249		$ 0
Total lease liabilities	$ 360	$ 400

CONVERTIBLE NOTES - Schedule of

CONVERTIBLE NOTES - Schedule of Convertible Notes (Details) - USD ($)		6 Months Ended	12 Months Ended
	May 31, 2022	Jun. 30, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Default premium		$ 178,000	$ 0
Conversion of note into common shares	$ (151,772)
Convertible Debt
Debt Instrument [Line Items]
Principal amount		2,120,000	1,060,000
Less: Original issuance discount ("OID")		(120,000)	(60,000)
Less: Debt issuance costs		(275,000)	(229,000)
Net proceeds		1,725,000	771,000
Conversion of note into common shares		(1,260,000)	(230,000)
Accretion of OID and amortization of debt issuance costs		309,000	71,000
Carrying amount		$ 952,000	$ 612,000

CONVERTIBLE NOTES - Narrative (

CONVERTIBLE NOTES - Narrative (Details)				1 Months Ended	3 Months Ended	6 Months Ended		12 Months Ended
	May 31, 2022 USD ($) $ / shares shares	Nov. 17, 2021 USD ($)	Nov. 14, 2021 USD ($) day $ / shares	Aug. 12, 2022 USD ($) $ / shares shares	Jun. 30, 2022 USD ($) d $ / shares shares	Jun. 30, 2022 USD ($) d $ / shares shares	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	May 17, 2022 USD ($)	Mar. 25, 2022 USD ($) $ / shares
Debt Instrument [Line Items]
Conversion price (in USD per share) | $ / shares	$ 0.04
Converted instrument, shares issued (in shares) | shares	3,751,971				7,172,244	13,976,525
Decrease in convertible note						$ 1,030,000	$ 0
Interest expense						$ 600,000
Conversion of convertible debt	$ 151,772
QTD
Debt Instrument [Line Items]
Conversion price (in USD per share) | $ / shares					$ 0.05	$ 0.05
YTD
Debt Instrument [Line Items]
Conversion price (in USD per share) | $ / shares					$ 0.07	$ 0.07
Subsequent Public Or Private Offering
Debt Instrument [Line Items]
Redemption price, percentage			20%
Convertible Debt
Debt Instrument [Line Items]
Debt face value			$ 5,300,000
Principal amount		$ 1,060,000							$ 130,000	$ 1,060,000
Discount percentage		6%
Net proceeds		$ 1,000,000
Stated interest rate		15%
Conversion price (in USD per share) | $ / shares			$ 0.2611							$ 0.1508
Threshold percentage of stock price trigger			120%
Threshold trading days			5		5	5
Redemption price premium, percentage			15%
Accrued interest					$ 29,000	$ 29,000		$ 0
Decrease in convertible note					400,000	1,000,000
Interest expense					$ 0
Conversion of convertible debt						$ 1,260,000		$ 230,000
Convertible Debt | Subsequent Event
Debt Instrument [Line Items]
Conversion price (in USD per share) | $ / shares				$ 0.03
Converted instrument, shares issued (in shares) | shares				7,308,876
Interest expense				$ 0
Conversion of convertible debt				$ 200,000
Convertible Debt | Alternative Conversion Price, Option One
Debt Instrument [Line Items]
Threshold percentage of stock price trigger			90%
Floor price (in USD per share) | $ / shares			$ 0.01
Convertible Debt | Alternative Conversion Price, Option Two
Debt Instrument [Line Items]
Threshold percentage of stock price trigger			97%
Convertible Debt | Default
Debt Instrument [Line Items]
Redemption price premium, percentage			10%
VWAP of common stock, constitutes price default (in USD per share) | $ / shares					$ 0.10	$ 0.10
Convertible Debt | Subsequent Public Or Private Offering
Debt Instrument [Line Items]
Redemption price premium, percentage			5%

DEBT (Details)

DEBT (Details) - Unsecured Note Payable - USD ($)	1 Months Ended
	Oct. 31, 2021	Oct. 31, 2020	Jun. 30, 2022
2021 Premium Finance Agreement
Debt Instrument [Line Items]
Amount financed	$ 400,000
Stated interest rate	4.17%
Monthly payment	$ 45,000
Outstanding balance			$ 100,000
2020 Premium Finance Agreement
Debt Instrument [Line Items]
Amount financed		$ 700,000
Stated interest rate		3.60%
Monthly payment		$ 63,000
Outstanding balance			$ 0

STOCKHOLDERS EQUITY - Narrative

STOCKHOLDERS EQUITY - Narrative (Details) $ / shares in Units, $ in Thousands			1 Months Ended	3 Months Ended			6 Months Ended
	Mar. 30, 2022 USD ($) vote $ / shares shares	Dec. 08, 2020 USD ($) day	Mar. 31, 2022 USD ($)	Jun. 30, 2022 USD ($) yr $ / shares shares	Mar. 31, 2022 USD ($) shares	Jun. 30, 2021 USD ($) shares	Jun. 30, 2022 USD ($) yr $ / shares shares	Jun. 30, 2021 USD ($) shares	Jun. 06, 2022 shares	Jun. 05, 2022 shares	Mar. 29, 2022 shares	Dec. 31, 2021 $ / shares shares
Subsidiary, Sale of Stock [Line Items]
Common stock issued for services					$ 384
Capital stock authorized (in shares) | shares									800,000,000	200,000,000
Common stock authorized (in shares) | shares	790,000,000			790,000,000			790,000,000		790,000,000	190,000,000	190,000,000	190,000,000
Securities called by preferred stock and warrants (in shares) | shares	10,000,000
Preferred stock par value (in USD per share) | $ / shares	$ 0.0001			$ 0.0001			$ 0.0001					$ 0.0001
Proceeds from issuance of preferred stock	$ 700		$ 700
Payments of stock issuance costs	600
Deduction from proceeds, related to agent’s fees and other offering expenses	$ 100
Preferred stock, stated value, subjected to conversion (in USD per share) | $ / shares	$ 1,000
Preferred stock, convertible into common stock (in shares) | shares	10,000,000
Preferred stock conversion price (in USD per share) | $ / shares	$ 0.07
Number of shares underlying warrants (in shares) | shares				10,750,000			10,750,000					0
Fair value recorded as additional offering cost	$ 100
Beneficial conversion charge				$ 900
Number of votes per share of common stock underlying the preferred stock | vote	170,000
Preferred stock authorized (in shares) | shares	800,000,000			10,000,000			10,000,000				200,000,000	10,000,000
Maximum
Subsidiary, Sale of Stock [Line Items]
Stock split, conversion ratio	0.1
Minimum
Subsidiary, Sale of Stock [Line Items]
Stock split, conversion ratio	0.0025
Warrants with $0.1000 Exercise Price
Subsidiary, Sale of Stock [Line Items]
Exercise price (in USD per share) | $ / shares	$ 0.10			$ 0.1000			$ 0.1000
Number of shares underlying warrants (in shares) | shares				10,000,000			10,000,000					0
Warrants with $0.0875 Exercise Price
Subsidiary, Sale of Stock [Line Items]
Exercise price (in USD per share) | $ / shares	$ 0.0875			$ 0.0875			$ 0.0875
Number of shares underlying warrants (in shares) | shares	750,000			750,000			750,000					0
Contractual term
Subsidiary, Sale of Stock [Line Items]
Fair value of the warrants issued, assumptions | yr				3			3
Expected volatility rate
Subsidiary, Sale of Stock [Line Items]
Fair value of the warrants issued, assumptions				1.040			1.040
Risk-free interest rate
Subsidiary, Sale of Stock [Line Items]
Fair value of the warrants issued, assumptions				0.025			0.025
Expected dividend rate
Subsidiary, Sale of Stock [Line Items]
Fair value of the warrants issued, assumptions				0			0
Series A Preferred Stock
Subsidiary, Sale of Stock [Line Items]
Stock issued during period (in shares) | shares	700
Common Stock
Subsidiary, Sale of Stock [Line Items]
Common stock issued for services (in shares) | shares				3,496,000	3,496,000
Common stock issued for services				$ 400
Preferred Stock
Subsidiary, Sale of Stock [Line Items]
Proceeds from issuance of preferred stock							$ 400
Payments of stock issuance costs							100
Preferred stock, net of stock issuance costs							300
Warrants
Subsidiary, Sale of Stock [Line Items]
Payments of stock issuance costs							100
Proceeds from warrants issued							300
Warrants, net of stock issuance costs							$ 200
SPA
Subsidiary, Sale of Stock [Line Items]
Value of shares (up to)		$ 10,000
Number of specified trading days between directions to purchase stock | day		3
Common stock sold (in shares) | shares						1,669,086		7,796,356
Proceeds recognized						$ 600		$ 3,900

STOCKHOLDERS EQUITY - Warrants

STOCKHOLDERS EQUITY - Warrants Outstanding (Details) - $ / shares shares in Thousands	Jun. 30, 2022	Mar. 30, 2022	Dec. 31, 2021
Subsidiary, Sale of Stock [Line Items]
Number of shares underlying warrants (in shares)	10,750		0
Warrants with $0.1000 Exercise Price
Subsidiary, Sale of Stock [Line Items]
Exercise price (in USD per share)	$ 0.1000	$ 0.10
Number of shares underlying warrants (in shares)	10,000		0
Warrants with $0.0875 Exercise Price
Subsidiary, Sale of Stock [Line Items]
Exercise price (in USD per share)	$ 0.0875	$ 0.0875
Number of shares underlying warrants (in shares)	750	750	0

STOCK-BASED COMPENSATION - Narr

STOCK-BASED COMPENSATION - Narrative (Details) - USD ($) $ in Millions			1 Months Ended	6 Months Ended
	Mar. 30, 2022	Jan. 01, 2022	Mar. 31, 2022	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Jun. 11, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unvested options granted (in shares)				0
Increase (decrease) in number of shares authorized (in shares)	8,000,000
Unrecognized compensation cost				$ 0.6
Unrecognized weighted average period				7 months 28 days
Options Outside the Amended 2013 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Performance-based options outstanding (in shares)				4,250,000
Unvested stock options outstanding (in shares)				6,750,000
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of common stock from net exercise of stock options (in shares)				0	0
Amended 2013 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares authorized under plan (in shares)						38,976,000
Annual increase to shares authorized for issuance under the Plan as percent of common stock outstanding percentage							4%
Annual increase to shares authorized for issuance under the Plan (in shares)							4,000,000,000
Additional shares authorized (in shares)		0
Shares cancelled (in shares)			9,000,000
Unvested options granted (in shares)			7,000,000
Authorized unissued shares reserved and available for issuance upon exercise and conversion of outstanding awards (in shares)				4,993,000

STOCK-BASED COMPENSATION - Opti

STOCK-BASED COMPENSATION - Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended	12 Months Ended
	Jun. 30, 2022	Dec. 31, 2021
Number of Shares
Options outstanding, granted (in shares)	0
Equity Option
Number of Shares
Options outstanding, beginning balance (in shares)	30,163,000
Options outstanding, granted (in shares)	0
Options outstanding, exercised (in shares)	0
Options outstanding, forfeited (in shares)	(8,517,000)
Options outstanding, ending balance (in shares)	21,646,000	30,163,000
Options outstanding, exercisable (in shares)	19,120,000
Options outstanding, vested or expected to vest (in shares)	21,646,000
Weighted Average Exercise Price
Beginning balance (in USD per share)	$ 0.49
Granted (in USD per share)	0
Exercised (in USD per share)	0
Forfeited (in USD per share)	0.50
Ending balance (in USD per share)	0.49	$ 0.49
Weighted average exercise price, exercisable (in USD per share)	0.50
Weighted average exercise price, vested or expected to vest (in USD per share)	$ 0.49
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted average remaining contract term	3 years 7 months 6 days	5 years 6 months
Weighted average remaining contract term, exercisable	3 years 10 months 24 days
Weighted average remaining contract term, vested or expected to vest	3 years 7 months 6 days
Aggregate intrinsic value	$ 0	$ 0
Aggregate intrinsic value, exercisable	0
Aggregate intrinsic value, vested or expected to vest	$ 0

STOCK-BASED COMPENSATION - Base

STOCK-BASED COMPENSATION - Based Compensation (Details) - $ / shares	3 Months Ended	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-Based Payment Arrangement [Abstract]
Volatility	132.10%		133.70%
Risk-Free Interest Rate	0.80%		0.90%
Expected Term (in years)	5 years 5 months 26 days		5 years 7 months 9 days
Dividend Rate	0%		0%
Fair Value Per Share on Grant Date (in USD per share)	$ 0.32		$ 0.49
Options outstanding, granted (in shares)		0

NET LOSS PER SHARE - Antidiluti

NET LOSS PER SHARE - Antidilutive Shares (Details) - shares shares in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares (in shares)	46,033	39,333	46,033	39,333
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares (in shares)	17,396	26,333	17,396	26,333
Performance stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares (in shares)	11,000	13,000	11,000	13,000
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares (in shares)	10,750	0	10,750	0
Convertible notes
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares (in shares)	6,887	0	6,887	0

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details)				6 Months Ended
	Jul. 29, 2022 lawsuitAction	Jul. 28, 2022 USD ($) lawsuitAction	Apr. 13, 2021 lawsuit	Jun. 30, 2022 USD ($)	Apr. 27, 2022 USD ($)
Loss Contingencies [Line Items]
Number of shareholder derivative suits filed | lawsuit			5
Issuance of interim awarding related to purchase of PSL and other advance payments					$ 300,000
Termination severance and other post-termination compensation and benefits under his employment agreement					$ 600,000
Net amount due to Mona Jr. included in accrued expenses				$ 300,000
Subsequent Event
Loss Contingencies [Line Items]
Number of derivative actions | lawsuitAction		6
Number of shareholder derivative lawsuits approved | lawsuitAction	6
Number of shareholder derivative lawsuits actions pending for approval | lawsuitAction	5
Smith Complaint
Loss Contingencies [Line Items]
Preliminary settlement				$ 712,500
Berry Complaint | Subsequent Event
Loss Contingencies [Line Items]
Payment of plaintiffs' attorneys' fees for derivative legal settlement		$ 275,000,000

SEGMENT INFORMATION (Details)

SEGMENT INFORMATION (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) segment	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Segment Reporting Information [Line Items]
Number of operating segments | segment			2
Product sales, net	$ 4,138	$ 5,128	$ 8,585	$ 9,972
Gross profit	1,270	2,290	2,426	4,648
Research and development expense	102	225	223	411
Selling, general and administrative expense	3,483	5,575	6,033	10,860
Operating loss	(2,315)	(3,510)	(3,830)	(6,623)
Consumer Products Segment
Segment Reporting Information [Line Items]
Product sales, net	4,138	5,128	8,585	9,972
Gross profit	1,270	2,290	2,426	4,648
Research and development expense	84	126	201	254
Selling, general and administrative expense	3,474	5,565	5,993	10,835
Operating loss	(2,288)	(3,401)	(3,768)	(6,441)
Specialty Pharmaceutical Segment
Segment Reporting Information [Line Items]
Product sales, net	0	0	0	0
Gross profit	0	0	0	0
Research and development expense	18	99	22	157
Selling, general and administrative expense	9	10	40	25
Operating loss	(27)	$ (109)	(62)	$ (182)
Intangible assets	$ 1,500		$ 1,500		$ 1,500

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Net operating loss, tax benefit recognized	$ 0	$ 0	$ 0	$ 0

RELATED PARTIES (Details)

RELATED PARTIES (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended		3 Months Ended	6 Months Ended	12 Months Ended
	Mar. 31, 2017	Jul. 31, 2016	Dec. 31, 2020	Jun. 30, 2022	Dec. 31, 2020	Dec. 31, 2019	Jun. 30, 2019
Related Party Transaction [Line Items]
Employee portion of payroll taxes paid					$ 0.2
Former President and CEO
Related Party Transaction [Line Items]
Due from former President and CEO				$ 6.4
Former President and CEO | Accrued Expenses
Related Party Transaction [Line Items]
Payroll taxes payable			$ 6.2		$ 6.2
Former President and CEO | Prepaid Expenses and Other
Related Party Transaction [Line Items]
Due from former President and CEO							$ 6.2
Write-off of previously recorded receivable			$ 6.2
Former President and CEO | Selling, General and Administrative Expenses
Related Party Transaction [Line Items]
Employer portion of FICA taxes						$ 0.2
Stock options | Former President and CEO
Related Party Transaction [Line Items]
Extension of period to exercise stock options						5 years
Unvested options vested (in shares)				11,300,000
Weighted average exercise price of outstanding vested options (in USD per share)				$ 0.42
Stock options issued (in shares)	5,000,000	6,000,000
Unvested stock options outstanding (in shares)				6,750,000
Stock based compensation expense						$ 2.7
Restricted Stock Units (RSUs) | Former President and CEO
Related Party Transaction [Line Items]
Stock based compensation expense						$ 5.1
Vested RSU's (in shares)						2,950,000